Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Abbott and Ranbaxy settle patent litigation
Abbott laboratories has settled a patent litigation case against Ranbaxy, allowing it to launch
generic version of cholesterol-lowering medicine Tricor. The annual sales for Abbott from
Tricor and Triplix are around US $1bn in the US markets alone. With respect to Ranbaxy, it
cannot be ascertained when it would be able to launch the drug in the US. Abbott had
earlier settled with Teva (145mg dosage) for the same medicine, permitting it to launch the
low-priced version by March 2011. There are three other drug makers wanting to launch
their version of the same drug ahead of Tricor’s patent expiry in January 2018. We are
positive on the development for Ranbaxy. However, as there are no concrete details
regarding the launch of the drug by the company, we remain Neutral on the stock.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Abbott and Ranbaxy settle patent litigation
Abbott laboratories has settled a patent litigation case against Ranbaxy, allowing it to launch
generic version of cholesterol-lowering medicine Tricor. The annual sales for Abbott from
Tricor and Triplix are around US $1bn in the US markets alone. With respect to Ranbaxy, it
cannot be ascertained when it would be able to launch the drug in the US. Abbott had
earlier settled with Teva (145mg dosage) for the same medicine, permitting it to launch the
low-priced version by March 2011. There are three other drug makers wanting to launch
their version of the same drug ahead of Tricor’s patent expiry in January 2018. We are
positive on the development for Ranbaxy. However, as there are no concrete details
regarding the launch of the drug by the company, we remain Neutral on the stock.
No comments:
Post a Comment